DSM Venturing Invests in U.S. Probiotic Firm

HEERLEN, NetherlandsDSM Venturing, the corporate venture capital unit of Royal DSM N.V., participated in a $12 million financing round with Boston-based Capital Resource Partners for Ganeden Biotech Inc., a U.S. probiotics company marketing dietary supplements for digestive health. Ganeden (GanedenLabs.com) uses the spore-forming and lactic-acid-producing bacterium Bacillus coagulans. The proprietary probiotic strains, including Ganeden BC30, are designed to have an extended shelf life, bioavailability and resilience during processing.